Clinical Trials and Studies

Your participation matters. Help us discover and cure!

Contact us at (800) USC-CARE (800-872-2273)

We're sorry, but this trial is no longer enrolling volunteers.

9L-11-7: A Phase 2 Study of SAR245409 in Patients with Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma


There is a 21 day screening period followed by 28 day cycles. Patients will continue to receive SAR245409 as long as there is clinical benefit or until a study withdrawal criterion is met. The last posttreatment visit will be 30 days after the last dose or until IMP-related toxicities have resolved or are deemed irreversible, whichever is later.


Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.

Inclusion and Exclusion Criteria

  • - Tissue from an archived or fresh tumor sample - A peripheral blood buffy coat sample is required for CLL/SLL. - Patient has mantle cell lymphoma (MCL), follicular lymphoma (FL), or chronic lymphocytic leukemia (CLL)/SLL or diffuse large B cell lymphoma - Patient > or = 18 years old
  • Patients with DLBCL will have ECOG < or = 1 - Adequate white blood cells and hemoglobin - Good kidney and liver function - Fasting glucose < 160 mg/dL - No other malignancy - Use of adequate birth control

  • Treatment with cytotoxic chemotherapy, biologic agents, investigational therapies within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks of study enrollment
  • Treatment with a small-molecule kinase inhibitor within 2 weeks, or 5 half lives of the drug or its active metabolites (whichever is longer) of study enrollment
  • Prior treatment with a PI3K, mTOR, or Akt inhibitor. Prior treatment of MCL with temsirolimus is permitted in patients enrolled from countries where it is licensed for this indication.
  • Radiation therapy within 2 weeks of enrollment
  • Autologous stem cell transplantation within 16 weeks of enrollment
  • Prior allogeneic transplantation except for patients with R/R DLBCL who meet inclusion criteria
  • Central nervous system (CNS) or leptomeningeal involvement. Patients with DLBCL may have active CNS or leptomeningeal involvement.
  • Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (anti-HCV) serology
  • Primary CNS lymphoma
  • Primary mediastinal B-lymphoma The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


  • California

    • Investigational Site Number 840012, Los Angeles, California, 90033
  • Arkansas

    • Investigational Site Number 840018, Hot Springs, Arkansas, 71913
  • Missouri

    • Investigational Site Number 840015, St Louis, Missouri, 63110
  • Kentucky

    • Investigational Site Number 840007, Paducah, Kentucky, 42002
    • Investigational Site Number 840013, Lexington, Kentucky, 40536
  • Illinois

    • Investigational Site Number 840011, Maywood, Illinois, 60153
  • Germany

    • Investigational Site Number 276001, Ulm, 89081
  • France

    • Investigational Site Number 250003, Villejuif Cedex, 94805
    • Investigational Site Number 250004, Rennes, 35033
Powered by SC CTSI